• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1, 2009

Posted on: Tuesday, 24 March 2009, 06:30 CDT

PRINCETON, N.J., March 24 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that it will report its fourth quarter and year-end 2008 results on Wednesday, April 1, 2009. The Company will hold a conference call that same day to discuss the results at 11:00 am EDT. Interested parties should call 866-271-5140 (domestic) or 617-213-8893 (international), with passcode 42480759 to access the call. You may also access this call via the Internet at:

http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=2119681

For those who are unavailable to listen to the live broadcast, a replay will be available through May 1, 2009 and can be accessed by dialing 888-286-8010 (domestic), and 617-801-6888 (international). The passcode is 36656033.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY(TM), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010. For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Edward J. Quilty Chairman and CEO equilty@dermasciences.com (609) 514-4744 Allen & Caron Inc Rudy Barrio (US Investors) r.barrio@allencaron.com (212) 691-8087 Brian Kennedy (Media) brian@allencaron.com (212) 691-8087

SOURCE Derma Sciences, Inc.

Source: PR Newswire

More News in this Category